(Q45228579)

11 December 2017

title

A novel chimpanzee serotype-based adenoviral vector as delivery tool for cancer vaccines (English)

1 reference

11 December 2017

1 reference

0 references

8

1 reference

11 December 2017

Daniela Peruzzi

1

1 reference

11 December 2017

Sridhar Dharmapuri

2

1 reference

11 December 2017

Agostino Cirillo

3

1 reference

11 December 2017

Bruno Ercole Bruni

4

1 reference

11 December 2017

Alfredo Nicosia

5

1 reference

11 December 2017

Riccardo Cortese

6

1 reference

11 December 2017

Stefano Colloca

7

1 reference

11 December 2017

Nicola La Monica

9

1 reference

11 December 2017

Luigi Aurisicchio

10

1 reference

11 December 2017

language of work or name

English

0 references

publication date

20 January 2009

1 reference

11 December 2017

1 reference

11 December 2017

volume

27

1 reference

11 December 2017

issue

9

1 reference

11 December 2017

page(s)

1293-1300

1 reference

Adenoviruses from patients with AIDS: a plethora of serotypes and a description of five new serotypes of subgenus D (types 43-47)

11 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.051

Two new candidate adenovirus serotypes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.051

Emerging adenoviral vectors for stable correction of genetic disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.051

Adenovirus vector induced innate immune responses: impact upon efficacy and toxicity in gene therapy and vaccine applications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.051

Viral recombinant vaccines to the E6 and E7 antigens of HPV-16

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.051

A replication-defective human adenovirus recombinant serves as a highly efficacious vaccine carrier.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.051

Adult dogs receiving a rabies booster dose with a recombinant adenovirus expressing rabies virus glycoprotein develop high titers of neutralizing antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.051

Preserved CD4+ central memory T cells and survival in vaccinated SIV-challenged monkeys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.051

Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.051

Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.051

Safety and Immunogenicity of a Replication‐Incompetent Adenovirus Type 5 HIV‐1 Clade Bgag/pol/nefVaccine in Healthy Adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.051

DNA gag/adenovirus type 5 (Ad5) gag and Ad5 gag/Ad5 gag vaccines induce distinct T-cell response profiles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.051

Comparative Immunogenicity in Rhesus Monkeys of DNA Plasmid, Recombinant Vaccinia Virus, and Replication-Defective Adenovirus Vectors Expressing a Human Immunodeficiency Virus Type 1 gag Gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.051

A simian replication-defective adenoviral recombinant vaccine to HIV-1 gag.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.051

Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.051

Transient depletion of CD4 lymphocyte improves efficacy of repeated administration of recombinant adenovirus in the ornithine transcarbamylase deficient sparse fur mouse.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.051

Artificial envelopment of nonenveloped viruses: enhancing adenovirus tumor targeting in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.051

Adenovirus vectors composed of subgroup B adenoviruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.051

Efficient immunization of rhesus macaques with an HCV candidate vaccine by heterologous priming-boosting with novel adenoviral vectors based on different serotypes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.051

A system for the propagation of adenoviral vectors with genetically modified receptor specificities

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.051

Modulation of adenovirus vector tropism via incorporation of polypeptide ligands into the fiber protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.051

Changing the adenovirus fiber for retaining gene delivery efficacy in the presence of neutralizing antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.051

Encapsulation of recombinant adenovirus into alginate microspheres circumvents vector-specific immune response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.051

Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.051

Immunogenicity of heterologous prime-boost regimens involving recombinant adenovirus serotype 11 (Ad11) and Ad35 vaccine vectors in the presence of anti-ad5 immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.051

Recent advances in the development of HIV-1 vaccines using replication-incompetent adenovirus vectors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.051

Development of nonhuman adenoviruses as vaccine vectors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.051

Recombinant ovine atadenovirus induces a strong and sustained T cell response against the hepatitis C virus NS3 antigen in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.051

Effect of preexisting immunity to adenovirus human serotype 5 antigens on the immune responses of nonhuman primates to vaccine regimens based on human- or chimpanzee-derived adenovirus vectors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.051

Chimpanzee-origin adenovirus vectors as vaccine carriers.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.051

Efficacy of severe acute respiratory syndrome vaccine based on a nonhuman primate adenovirus in the presence of immunity against human adenovirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.051

A chimpanzee-origin adenovirus vector expressing the rabies virus glycoprotein as an oral vaccine against inhalation infection with rabies virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.051

Contrasting effects of human, canine, and hybrid adenovirus vectors on the phenotypical and functional maturation of human dendritic cells: implications for clinical efficacy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.051

Frequency, proliferation, and activation of human memory T cells induced by a nonhuman adenovirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.051

Porcine adenoviral vectors evade preexisting humoral immunity to adenoviruses and efficiently infect both human and murine cells in culture

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.051

Tumor antigen-based immunotherapy and immunoprevention of cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.051

DNA and Adenoviral Vectors Encoding Carcinoembryonic Antigen Fused to Immunoenhancing Sequences Augment Antigen-Specific Immune Response and Confer Tumor Protection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.051

Vectors encoding carcinoembryonic antigen fused to the B subunit of heat-labile enterotoxin elicit antigen-specific immune responses and antitumor effects.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.051

Adenovirus vaccination against neu oncogene exerts long-term protection from tumorigenesis in BALB/neuT transgenic mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.051

Efficient induction of T-cell responses to carcinoembryonic antigen by a heterologous prime-boost regimen using DNA and adenovirus vectors carrying a codon usage optimized cDNA

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.051

Immunogenicity and safety of a DNA prime/adenovirus boost vaccine against rhesus CEA in nonhuman primates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.051

Overcoming immunity to a viral vaccine by DNA priming before vector boosting

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.051

Carcinoembryonic antigen gene family: molecular biology and clinical perspectives

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.051

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.051

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.051

Therapeutic vaccination halts disease progression in BALB-neuT mice: the amplitude of elicited immune response is predictive of vaccine efficacy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.051

Early and multifocal tumors in breast, salivary, Harderian and epididymal tissues developed in MMTY-Neu transgenic mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.051

Individual mouse analysis of the cellular immune response to tumor antigens in peripheral blood by intracellular staining for cytokines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.051

Quantitative adenovirus neutralization assays based on the secreted alkaline phosphatase reporter gene: application in epidemiologic studies and in the design of adenovector vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.051

Mouse models expressing human carcinoembryonic antigen (CEA) as a transgene: evaluation of CEA-based cancer vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.051

CAR: a virus receptor within the tight junction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.051

Heparan sulfate glycosaminoglycans are receptors sufficient to mediate the initial binding of adenovirus types 2 and 5.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.051

The influence of blood on in vivo adenovirus bio-distribution and transduction.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.051

Adenovirus serotype 5 hexon mediates liver gene transfer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.051

Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.051

Partial protection against H5N1 influenza in mice with a single dose of a chimpanzee adenovirus vector expressing nucleoprotein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.051

Adenoviruses from human immunodeficiency virus-infected individuals, including two strains that represent new candidate serotypes Ad50 and Ad51 of species B1 and D, respectively

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.051

7 January 2021

inferred from DOI database lookup

Combinatorial blockade of calcineurin and CD28 signaling facilitates primary and secondary therapeutic gene transfer by adenovirus vectors in dystrophic (mdx) mouse muscles

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.051

7 January 2021

inferred from DOI database lookup

United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) Guidelines for the Welfare of Animals in Experimental Neoplasia (Second Edition)

1 reference

12 December 2020

Mice transgenic for the human carcinoembryonic antigen gene maintain its spatiotemporal expression pattern

1 reference

12 December 2020

Renewed promise. Annual AIDS vaccine meeting highlights recent data from clinical trials and lessons on recruitment and retention of volunteers.

1 reference

12 December 2020

Carcinoembryonic antigen: cell adhesion molecule and useful diagnostic marker.

1 reference

12 December 2020

10.1016/J.VACCINE.2008.12.051

Identifiers

DOI

1 reference

11 December 2017

0 references

1 reference